Showing 20 of 162 recruiting trials for “nasopharyngeal-carcinoma”
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
👨⚕️ zhenyu ding, MD, West China Hospital of Sichuan University, ChengDu, China📍 1 site📅 Started Oct 2024View details ↗
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
👨⚕️ Sakti Chakrabarti, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06713993 ↗
Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RecruitingNCT06550063 ↗
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
👨⚕️ John V Reynolds, MBBCh,MD, Trinity St James Cancer Institute📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06558786 ↗
Registry for Esophageal and Gastroesophageal Junction Cancer
👨⚕️ Daniela Molena, MD, Memorial Sloan Kettering Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
👨⚕️ Bo You, Doctor, Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University📍 1 site📅 Started Aug 2024View details ↗
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
👨⚕️ Melvin LK CHUA, MBBS, FRCR, PhD, FAMS, National Cancer Centre, Singapore📍 2 sites📅 Started Jul 2024View details ↗
RecruitingNCT06463392 ↗
Deep Learning-based sbORN Diagnostic Model
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Enrolling by InvitationNCT06475196 ↗
Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
RecruitingNCT06445088 ↗
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →